COVID-19: In Vitro Diagnostic Testing Policy 0557
U0003 Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R (Code deleted 5/11/2023)
U0004 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R (Code deleted 5/11/2023)
U0005 Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (List separately in addition to either HCPCS code U0003 or U0004) as described by CMS-2020-01-R2 (Code deleted 5/11/2023)
The source page for this article has moved or has expired.
Please visit the Billing Beat News or Beyond Billing Blog for relevant information or search our site for specific information related to this article.
Original source URL:
https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_Future/mm_0557_coveragepositioncriteria_covid-19_in_vitro_diagnostic_testing.pdf